No Data
No Data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
The Arbutus Biopharma Corporation (NASDAQ:ABUS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Last week saw the newest quarterly earnings release from Arbutus Biopharma Corporation (NASDAQ:ABUS), an important milestone in the company's journey to build a stronger business. Revenues fell
Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add
Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma with a Buy and maintains $4 price target.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)